A B S T R A C T Aspirin inhibits cyclooxygenase, thus preventing thromboxane A2 production in blood platelets and prostacyclin in vascular cells. Aspirin is rapidly hydrolyzed to salicylate in the circulation. The objectives of this study were (a) to evaluate whether administration of salicylate, though ineffective by itself, prevents the inhibitory effect of aspirin on platelet and/or vascular cyclooxygenase activity; (b) to verify whether salicylate accumulating in blood after aspirin administration interferes with the pharmacological activity of further doses of aspirin. Pretreatment of rats with sodium salicylate (25-100 mg/kg i.p.) resulted in dose-related prevention of the effect of a subsequent dose of aspirin (2.5-10 mg/kg i.v.) on both platelet and vascular cells. Sodium salicylate appeared to amplify the greater response of platelets to aspirin compared with vessel wall.
INTRODUCTION
Aspirin (acetylsalicylic acid) irreversibly inhibits cyclooxygenase, the enzyme that catalyzes the conversion of arachidonic acid into cyclic-prostaglandin endoperoxides (1) . These unstable compounds are in Received for publication 15 July 1981.
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turn metabolized preferentially to thromboxane A2 (TxA2)' in blood platelets (2) and to prostacyclin (PGI2) in vascular cells (3) . TxA2 can induce platelet aggregation and vasoconstriction, and PGI2 is a powerful inhibitor of platelet aggregation and a vasodilator (4) . If TxA2 and PGI2 production are both suppressed by aspirin, then the antithrombotic activity of this drug might be reduced (5) . Much effort has been devoted during the last few years to finding the most appropriate treatment schedule with aspirin to dissociate the drug's effects at platelet and vascular level. However studies in laboratory animals and in man have all been inconclusive so far (6) (7) (8) (9) (10) (11) (12) (13) (14) . The available results are based on studies with single doses ofaspirin, but any regimen using aspirin as a potential antithrombotic drug should be applied for long periods.
Aspirin is rapidly hydrolyzed in the body to salicylate (SA), which is eliminated slowly and can therefore accumulate in the circulation following repeated aspirin treatment (15) . Since SA by itself does not modify prostaglandin synthesis (4) no attention has been paid to the disposition of this substance in the body when discussing the potential antithrombotic effect ofaspirin. Several investigators reported recently that in vitro SA could prevent the inhibitory effect of aspirin on platelet and vascular cyclooxygenase activity (16) (17) (18) .
The purpose of the present work was dual: (a) To investigate whether SA-aspirin interaction could occur at platelet and/or vascular level in rats given both compounds. (b) To verify whether SA accumulating in blood from previous aspirin treatment could interfere with the pharmacological activity of further aspirin.
'Abbreviations used in this paper: AA, arachidonic acid; MDA, malondialdehyde; PG, prostaglandin; PGI2, prostacyclin; SA, salicylate; Tx, thromboxane. plasma with arachidonic acid (AA) (>99% pure, Nuchek Prep, Elysian, Minn.) (19) . PGI2 synthesis by rat thoracic aorta. Immediately after exsanguination the thoracic aorta was isolated, cleaned of adventitia, and flushed in situ with 5 ml of calcium-free tyrode solution. The vessel was then removed and a ring (-7 mg wet wt, 0.5 cm length) was cut in the middle part. The rings were immediately incubated at 37°C for 5 min in 100 ,ul of Tris-HCl buffer 0.15 M, pH 9.2 containing 25 ,uM AA. The supernatant buffer was then removed, rapidly frozen, and stored at -70°C until use. A standard curve of synthetic PGI2 (Upjohn Co., Kalamazoo, Mich.) was constructed in Tris HC1 buffer for each experiment and stored in an identical manner. PGI2 synthesis by the vessel wall was quantitated in two ways, using a bioassay of PGI2 (20) and a radioimmunoassay for 6-keto-PGF1. (21) .
Measurement ofblood SA levels. SA levels were measured by a spectrophotofluorimetric method (22) Malondialdehyde (MDA) and TxB2 production by platelets was measured respectively by a spectrophotometric method and by radioimmunoassay after incubation of platelet-rich 
RESULTS
Prevention by previous Na-SA administration of aspirin-induced inhibition of platelet and vascular cyclooxygenase activity (experiment A). Platelet cyclooxygenase activity (measured by the amount of MDA and TxB2 produced in platelet-rich plasma by 0.4 mM AA) was not modified by Na-SA (100 mg/kg i.p.) administered 1 h before testing (data not shown). In contrast, single doses of aspirin (2.5-10 mg/kg i.v.) resulted in complete inhibition of MDA production and a marked dose-related reduction of TxB2. When Na-SA was administered before aspirin, the inhibitory effect of the latter was significantly reduced as shown in Fig. 1 . The interaction was dependent on the doses of both drugs, being maximal when 100 mg/kg of Na-SA was followed by 2.5 mg/kg of aspirin and barely detectable when the same Na-SA dose was followed by 10 mg/kg of aspirin. Fig. 1 also reports the blood levels of SA measured just before aspirin administration.
Cyclooxygenase activity of thoracic aortic rings (measured by the amount of PGI2 activity and 6-ketoPGFia released upon incubation-with 25 ,tM AA) was not modified by Na-SA at any dose (data not shown). In contrast, aspirin induced a dose-related inhibition of cyclooxygenase activity. When Na-SA was administered before aspirin, the inhibitory effect of the latter was significantly reduced as shown in Fig. 2 .
Both PGI2 activity and 6-keto-PGF,a levels were between 70 and 100% of control values at all drug combinations except when the lowest dose of Na-SA (25 mg/kg) was given before the highest dose of aspirin (10 mg/kg).
Prevention by SA accumulating after aspirin administration of aspirin-induced inhibition of vascular cyclooxygenase activity (experiment B). As reported in Fig. 3 three doses of aspirin (200 mg/kg i.p.) were administered 4 h apart. 24 h after the last dose, PGI2 activity had recovered by -50% and SA levels were -175 Ag/ml. At that moment the administration of a test dose of aspirin (5 mg/kg i.v.) did not modify PGI2 activity,. In contrast, it significantly inhibited PGI2 activity when given after 36 or 48 h, when SA levels had dropped to 50 ,ug/ml or less.
It can be excluded that the lack of inhibition of PGI2 activity by aspirin (after 24 h) was due to refractoriness 100 mg/kg i.p.) resulted in dose-related prevention of the effect of subsequent single doses of aspirin (from 2.5 to 10 mg/ kg i.v.) on both platelet and vascular cells. Although platelet cyclooxygenase showed higher sensitivity to aspirin than vascular cyclooxygenase, complete dissociation between these two effects could not be obtained. This was achieved however when rats were pretreated with Na-SA. As an example, both platelet and vascular cyclooxygenase were almost completely blocked by 10 mg/kg aspirin, whereas they were inhibited by 95 and 20%, respectively, when the same dose of aspirin was given after Na-SA (50 mg/kg). Thus, SA appears to amplify the difference in the response to aspirin of platelet and vascular cells (9) . Whether this newly discovered property of SA derives from a different sensitivity to and/or access of the drug at various cellular levels remains to be established. Nevertheless, our observation may constitute the experimental basis for an original approach aimed at resolving the "aspirin dilemma" in clinical practice (5) .
In the second part of this study the SA levels reached after administration of Na-SA were comparable to those after administration of aspirin, its parent molecule. It was thus possible to demonstrate a hitherto unrecognized pharmacological interaction between the endogenously formed metabolite and its parent molecule. Indeed, pretreatment of rats with high doses of aspirin resulted in blood SA levels high enough to block the inhibitory effect of a subsequent dose of aspirin on vascular PGI2. The interaction between endogenous SA and aspirin could only be studied at vascular level since recovery of PGI2 activity from aspirin inhibition was sufficient when relatively high blood levels of SA were still present. In contrast, the inhibitory effect of aspirin on platelets was still complete 24 h after administration (7, 19) , so that an experiment similar to that described for vascular cells could not be performed.
The interference with aspirin of its metabolite SA was obtained in rather critical experimental conditions. In fact, the relation of these high doses to those used in man remains to be established. Therefore, any extrapolation to clinical situations would be hazardous. However, the findings should be taken into account when interpreting results obtained with high dose aspirin or during repeated administration of this drug.
